Εμφανίζονται 1 - 20 Αποτελέσματα από 134 για την αναζήτηση '"адренорецепторы"', χρόνος αναζήτησης: 0,65δλ Περιορισμός αποτελεσμάτων
  1. 1
    Academic Journal

    Πηγή: Vestnik Moskovskogo universiteta. Seriya 16. Biologiya; Том 79, № 2 (2024); 102-111 ; Вестник Московского университета. Серия 16. Биология; Том 79, № 2 (2024); 102-111 ; 0137-0952

    Περιγραφή αρχείου: application/pdf

    Relation: https://vestnik-bio-msu.elpub.ru/jour/article/view/1368/669; Shestopalov V.I., Panchin Y. Pannexins and gap junction protein diversity. Cell. Mol. Life Sci. 2008;65(3):376–394.; Penuela S., Gehi R., Laird D.W. The biochemistry and function of pannexin channels. Biochim. Biophys. Acta. 2013;1828(1):15–22.; Dahl G. ATP release through pannexon channels. Philos. Trans. R. Soc. B Biol. Sci. 2015;370(1672):20140191.; Taylor K.A., Wright J.R., Mahaut-Smith M.P. Regulation of Pannexin-1 channel activity. Biochem. Soc. Trans. 2015;43(3):502–507.; Billaud M., Chiu Y.H., Lohman A.W., Parpaite T., Butcher J.T., Mutchler S.M., DeLalio L.J., Artamonov M.V., Sandilos J.K., Best A.K., Somlyo A.V., Thompson R.J., Le T.H., Ravichandran K.S., Bayliss D.A., Isakson B.E. A molecular signature in the pannexin1 intracellular loop confers channel activation by the α1 adrenoreceptor in smooth muscle cells. Sci. Signal. 2015;8(364):ra17.; Кирюхина О.О., Гайнуллина Д.К., Панчин Ю.В., Шестопалов В.И., Тарасова О.С. Изменения пуринергической регуляции артерий брыжейки у мышей с нокаутом гена паннексина 1. Биологические мембраны. 2017;34(6):137–146.; Billaud M., Lohman A.W., Straub A.C., Looft-Wilson R., Johnstone S.R., Araj C.A., Best A.K., Chekeni F.B., Ravichandran K.S., Penuela S., Laird D.W., Isakson B.E. Pannexin1 regulates α1-adrenergic receptor- mediated vasoconstriction. Circ. Res. 2011;109(1):80–85.; Dunaway L.S., Billaud M., Macal E., Good M.E., Medina C.B., Lorenz U., Ravichandran K., Koval M., Isakson B.E. Amount of Pannexin 1 in smooth muscle cells regulates sympathetic nerve-induced vasoconstriction. Hypertension. 2023;80(2):416–425.; Grimmer B., Krauszman A., Hu X., Kabir G., Connelly K.A., Li M., Grune J., Madry C., Isakson B.E., Kuebler W.M. Pannexin 1: a novel regulator of acute hypoxic pulmonary vasoconstriction. Cardiovasc. Res. 2022;118(11):2535–2547.; Ladd Z., Su G., Hartman J., Lu G., Hensley S., Upchurch G.R., Sharma A.K. Pharmacologic inhibition by spironolactone attenuates experimental abdominal aortic aneurysms. Front. Cardiovasc. Med. 2023;10(2):555–567.; Vanlandewijck M., He L., Mäe M.A., Andrae J., Ando K., Del Gaudio F., Nahar K., Lebouvier T., Laviña B., Gouveia L., Sun Y., Raschperger E., Räsänen M., Zarb Y., Mochizuki N., Keller A., Lendahl U., Betsholtz C. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554(7693):475–480.; Reho J.J., Zheng X., Fisher S.A. Smooth muscle contractile diversity in the control of regional circulations. Am. J. of Physiol. Heart Circ. Physiol. 2014;306(2):H163–H172.; Takahashi S., Hitomi J., Satoh Y.I., Takahashi T., Asakura H., Ushiki T. Fine structure of the mouse portal vein in relation to its peristaltic movement. Arch. Histol. Cytol. 2002;65(1):71–82.; Guimarāes C.L., Calixto J.B., Rae G.A. Potent constrictor actions of endothelin-1, endothelin-2, and endothelin-3 in rat isolated portal vein. Hypertension. 1992;19(2):II79–II86.; Печкова М.Г., Кирюхина О.О., Виноградова О.Л., Тарасова О.С. Исследование сократительной активности портальной вены мыши в полетном эксперименте «Бион-М2»: обоснование актуальности и разработка экспериментальной модели. Авиакосмическая и экологическая медицина. 2023;57(5):141–148.; Andelova K., Benova T.E., Bacova B.S., Sykora M., Prado N.J., Diez E.R., Hlivak P., Tribulova N. Cardiac connexin-43 hemichannels and pannexin1 channels: Provocative antiarrhythmic targets. Int. J. Mol. Sci. 2021;22(1):260.; Kienitz M-C., Bender K., Dermietzel R., Pott L., Zoidl G. Pannexin 1 constitutes the large conductance cation channel of cardiac myocytes. J. Biol. Chem. 2011;286(1):290–298.; Battulin N., Kovalzon V.M., Korablev A., Serova I., Kiryukhina O.O., Pechkova M.G., Bogotskoy K.A., Tarasova O.S., Panchin Y. Pannexin 1 transgenic mice: human diseases and sleep-wake function revision. Int. J. Mol. Sci. 2021;22(10):5269; Kountz T.S., Lee K.S., Aggarwal-Howarth S., Curran E., Park J.M., Harris D.A., Stewart A., Hendrickson J., Camp N.D., Wolf-Yadlin A., Wang E.H., Scott J.D., Hague C. Endogenous N-terminal domain cleavage modulates α1D-Adrenergic receptor pharmacodynamics. J. Biol. Chem. 2016;291(35):18210–18221.; Koval M., Cwiek A., Carr T., Good M.E., Lohman A.W., Isakson B.E. Pannexin 1 as a driver of inflammation and ischemia-reperfusion injury. Purinergic Signal. 2021;17(4):521–531.; Van Helden D.F., Imtiaz M.S. Venous vasomotion. Adv. Exp. Med. Biol. 2019;1124:313–328.; Whyte-Fagundes P., Kurtenbach S., Zoidl C., Shestopalov V.I., Carlen P.L., Zoidl G. A potential compensatory role of panx3 in the VNO of a Panx1 knock out mouse model. Front. Mol. Neurosci. 2018;11:135.; Petric S., Klein S., Dannenberg L., Lahres T., Clasen L., Schmidt K.G., Ding Z., Donner B.C. Pannexin-1 Deficient mice have an increased susceptibility for atrial fibrillation and show a QT-prolongation phenotype. Cell. Physiol. Biochem. 2016;38(2):487–501.; Gurung I. S., Kalin A., Grace A.A., Huang C. L-H. Activation of purinergic receptors by ATP induces ventricular tachycardia by membrane depolarization and modifications of Ca2+ homeostasis. J. Mol. Cell. Cardiol. 2009;47(5):622–633.; Bao R., Shui X., Hou J., Li J., Deng X., Zhu X., Yang T. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice. Int. J. Mol. Med. 2016;38(3):969–75.

  2. 2
  3. 3
    Academic Journal

    Συνεισφορές: Тhe study was supported by a grant from the Russian Science Foundation (project № 23-25-00060), Исследование выполнено за счет гранта Российского научного фонда (проект № 23-25-00060)

    Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 39, № 1 (2024); 44-49 ; Сибирский журнал клинической и экспериментальной медицины; Том 39, № 1 (2024); 44-49 ; 2713-265X ; 2713-2927

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.sibjcem.ru/jour/article/view/1886/931; Файзуллоев А.И., Шукурова С.М., Рашидов И.М., Раджабова Г.М. Хроническая сердечная недостаточность: современные проблемы и пути их решения. Вестник последипломного образования в сфере здравоохранения. 2021;(2):93–100. URL: https://elibrary.ru/item.asp?id=47456873 (20.04.2023).; Кольцов А.В., Тыренко В.В., Сарана А.М., Язенок А.В., Коган Е.В., Ченцов Д.В. Распространенность сердечной недостаточности в условиях мегаполиса. Кардиология. 2022;62(12):50–56. DOI:10.18087/cardio.2022.12.n2294.; Hartupee J., Mann D.L. Neurohormonal activation in heart failure with reduced ejection fraction. Nat. Rev. Cardiol. 2017;14(1):30–38. DOI:10.1038/nrcardio.2016.163.; Agüero J., Almenar L., Montó F., Oliver E., Sánchez-Lázaro I., Vicente D. et al. Myocardial G protein receptor-coupled kinase expression correlates with functional parameters and clinical severity in advanced heart failure. J. Card. Fail. 2012;18(1):53–61. DOI:10.1016/j.cardfail.2011.10.008.; Wei W., Smrcka A.V. Subcellular β-adrenergic receptor signaling in cardiac physiology and disease. J. Cardiovasc. Pharmacol. 2022;80(3):334– 341. DOI:10.1097/FJC.0000000000001324.; Стрюк Р.И., Длусская И.Г. Адренореактивность и сердечно-сосудистая система. М: Медицина; 2003:160.; Хазова Е.В., Булашова О.В. Значение определения адренореактивности организма у пациентов с хронической сердечной недостаточностью. Практическая медицина. 2021;19(6):20–25. DOI:10.32000/2072-1757-2021-6-20-25.; Ватутин Н.Т., Шевелёк А.Н., Венжега В.В. Место пациентов с промежуточной фракцией выброса левого желудочка в общей популяции больных хронической сердечной недостаточностью. Архивъ внутренней медицины. 2021;11(2):111–121. DOI:10.20514/2226-6704-2021-11-2-111-121.; Хроническая сердечная недостаточность. Клинические рекомендации. Российское кардиологическое общество. Министерство здравоохранения РФ; 2020:183. URL: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_HSN-unlocked.pdf (27.02.2023).; Muslimova E., Rebrova T., Kondratieva D., Korepanov V., Sonduev E., Kozlov B. et al. Expression of the β1-adrenergic receptor (ADRB1) gene in the myocardium and β-adrenergic reactivity of the body in patients with a history of myocardium infraction. Gene. 2022;844:146820. DOI:10.1016/j.gene.2022.146820.; Оhnishi S.T., Barr J.K. A simplified method of quantitating protein using the biuret and phenol reagents. Anal. Biochem. 1978;86(1):193–200. DOI:10.1016/0003-2697(78)90334-2.; Зюбанова И.В., Фальковская А.Ю., Мордовин В.Ф., Пекарский С.Е., Манукян М.А., Цой Е.И. и др. Способ прогнозирования отдаленной антигипертензивной эффективности ренальной денервации у пациентов с резистентной артериальной гипертензией. Патент на изобретение 2767134 C1, 16.03.2022. Заявка № 2021119016 от 30.06.2021.; Шляхтина Н.В., Антоненок Е.А., Галанцев А.О. Клинико-патогенетические особенности хронической сердечной недостаточности с промежуточной фракцией выброса. Сибирский журнал клинической и экспериментальной медицины. 2021;36(3):45–50. DOI:10.29001/2073-8552-2021-36-3-45-50.; https://www.sibjcem.ru/jour/article/view/1886

  4. 4
    Academic Journal

    Συγγραφείς: N.V. Banadyha

    Πηγή: Sovremennaya pediatriya; № 6(94) (2018): Sovremennaya pediatriya; 9-13
    Современная педиатрия; № 6(94) (2018): Современная педиатрия; 9-13
    Сучасна педіатрія; № 6(94) (2018): Сучасна педіатрія; 9-13

    Περιγραφή αρχείου: application/pdf

  5. 5
    Academic Journal

    Συνεισφορές: This work was performed within the state assignment АААА-А15-115120910024-0., Исследование выполнено в рамках государственного задания АААА-А15-115120910024-0.

    Πηγή: Bulletin of Siberian Medicine; Том 20, № 3 (2021); 88-94 ; Бюллетень сибирской медицины; Том 20, № 3 (2021); 88-94 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2021-20-3

    Περιγραφή αρχείου: application/pdf

    Relation: https://bulletin.tomsk.ru/jour/article/view/4484/3051; https://bulletin.tomsk.ru/jour/article/view/4484/3078; Johansson G., Jonsson L., Lannek N., Blomgren L., Lindberg P., Poupa O. Severe stress-cardiopathy in pigs. American Heart Journal. 1974; 87 (4): 451–457. DOI:10.1016/0002-8703(74)90170-7.; Sato H. Tako-tsubo-like left ventricular dysfunction due to multivessel coronary spasm. Clinical Aspects of Myocardial Injury: From Ischemia to Heart Failure. 1990: 56–64.; Prokudina E.S., Kurbatov B.K., Zavadovsky K. V., Vrublevsky A. V., Naryzhnaya N. V., Lishmanov Y.B. et al. Takotsubo syndrome: clinical manifestations, etiology and pathogenesis. Current Cardiology Reviews. 2020; 16. DOI:10.2174/1573403X16666200129114330.; Stiermaier T., Moeller C., Oehler K., Desch S., Graf T., Eitel C. et al. Long-term excess mortality in takotsubo cardiomyopathy: predictors, causes and clinical consequences. European Journal of Heart Failure. 2016; 18 (6): 650–656. DOI:10.1002/ejhf.494.; Aoki Y., Kodera S., Ooe K. Further patient information; Takotsubo cardiomyopathy related to autonomic nervous system. International Journal of Cardiology. 2016; 209: 341. DOI:10.1016/j.ijcard.2016.02.056.; Vaccaro A., Despas F., Delmas C., Lairez O., Lambert E., Lambert G. et al. Direct evidences for sympathetic hyperactivity and baroreflex impairment in Tako Tsubo cardiopathy. PLoS One. 2014; 9 (3): e93278. DOI:10.1371/journal.pone.0093278.; Marfella R., Barbieri M., Sardu C., Rizzo M.R., Siniscalchi M., Paolisso P. et al. Effects of α-lipoic acid therapy on sympathetic heart innervation in patients with previous experience of transient takotsubo cardiomyopathy. Journal of Cardiology. 2016; 67 (2): 153–161. DOI:10.1016/j.jjcc.2015.07.012.; Christensen T.E., Bang L.E., Holmvang L., Skovgaard D.C., Oturai D.B., Søholm H. et al. 123 I-MIBG scintigraphy in the subacute state of Takotsubo cardiomyopathy. JACC: Cardiovascular Imaging. 2016; 9 (8): 982–990. DOI:10.1016/j.jcmg.2016.01.028.; Sobue Y., Watanabe E., Ichikawa T., Koshikawa M., Yamamoto M., Harada M. et al. Physically triggered Takotsubo cardiomyopathy has a higher in-hospital mortality rate. International Journal of Cardiology. 2017; 235: 87–93. DOI:10.1016/j.ijcard.2017.02.090.; Núñez-Gil I.J., Bernardo E., Feltes G., Escaned J., Mejía-Rentería H.D., De Agustín J.A. et al. Platelet function in Takotsubo cardiomyopathy. Journal of Thrombosis and Thrombolysis. 2015; 39 (4): 452–458. DOI:10.1007/s11239-014-1109-y.; Chernov V., Triss S., Skuridin V., Lishmanov Yu. Thallium-199: a new radiopharmaceutical for myocardial perfusion imaging. Int. J. Cardiac. Imaging 1996; 12 (2): 119–126. DOI:10.1007/BF01880743.; Чернов В.И., Медведева А.А., Синилкин И.Г., Зельчан Р.В., Брагина О.Д., Чойнзонов Е.Л. Ядерная медицина в диагностике и адресной терапии злокачественных новообразований. Бюллетень сибирской медицины. 2018; 17 (1): 220–231. DOI:10.20538/1682-0363-2018-1-220-231.; Miller D.G., Mallov S. Quantitative determination of stress-induced myocardial damage in rats. Pharmacology, Biochemistry and Behavior. 1977; 7 (2): 139–145. DOI:10.1016/0091-3057(77)90198-8.; Prokudina E., Maslov L., NaryzhnayA N., Tsibulnikov S., Lishmanov Y., Madias J. et al. Cardioprotective properties of opioid receptor agonists in rats with stress-induced cardiac injury. Physiological Research. 2019; 68 (3): 375–384. DOI:10.33549/physiolres.933946.; Takeuchi K., Okabe S., Takagi K. A new model of stress ulcer in the rat with pylorus ligation and its pathogenesis. The American Journal of Digestive Diseases. 1976; 21 (9): 782–788. DOI:10.1007/BF01073030.; Maslov L.N., Lishmanov Y.B., Oeltgen P.R., Barzakh E.I., Krylatov A. V., Govindaswami M. et al. Activation of peripheral δ2 opioid receptors increases cardiac tolerance to ischemia/reperfusion injury. Involvement of protein kinase C, NO-synthase, KATP channels and the autonomic nervous system. Life Sciences. 2009; 84 (19–20): 657–663. DOI:10.1016/J.LFS.2009.02.016.; Ray A., Sullivan R.M., Henke P.G. Adrenergic modulation of gastric stress pathology in rats: a cholinergic link. Journal of the Autonomic Nervous System. 1987; 20 (3): 265–268. DOI:10.1016/0165-1838(87)90155-X.; Bankwala Z., Hale S.L., Kloner R.A. Alpha-adrenoceptor stimulation with exogenous norepinephrine or release of endogenous catecholamines mimics ischemic preconditioning. Circulation. 1994; 90 (2): 1023–1028. DOI:10.1161/01.cir.90.2.1023.; Martins J.L.R., Rodrigues O.R.L., Da Silva D.M., Galdino P.M., De Paula J.R., Romão W. et al. Mechanisms involved in the gastroprotective activity of Celtis iguanaea (Jacq.) Sargent on gastric lesions in mice. Journal of Ethnopharmacology. 2014; 155 (3): 1616–1624. DOI:10.1016/j.jep.2014.08.006.; Loots W., De Clerck F. Differential effects of nebivolol on adrenoceptors in the heart and in resistance arterioles in the rat. Quantitative intravital microscopic analysis. European Journal of Pharmacology. 1990; 179 (1–2): 177–186. DOI:10.1016/0014-2999(90)90416-4.; Kwolek G., Zakrzeska A., Schlicker E., Göthert M., Godlewski G., Malinowska B. Central and peripheral components of the pressor effect of anandamide in urethane-anaesthetized rats. British Journal of Pharmacology. 2005; 145 (5): 567–575. DOI:10.1038/sj.bjp.0706195.; Mori A., Miwa T., Sakamoto K., Nakahara T., Ishii K. Pharmacological evidence for the presence of functional β3-adrenoceptors in rat retinal blood vessels. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2010; 382 (2): 119–126. DOI:10.1007/s00210-010-0526-5.; Taheri P., Choe E., Lippton H., Hyman A., Flint L., Ferrara J. Autonomic control of the regional hemodynamic response to scald. Life Sciences. 1995; 56 (9): 701–707. DOI:10.1016/0024-3205(94)00504-L.; Xue R.Q., Sun L., Yu X.J., Li D.L., Zang W.J. Vagal nerve stimulation improves mitochondrial dynamics via an M3 receptor/CaMKKβ/AMPK pathway in isoproterenol-induced myocardial ischaemia. Journal of Cellular and Molecular Medicine. 2017; 21 (1): 58–71. DOI:10.1111/jcmm.12938.; Zhao M., Jia H.H., Liu L.Z., Bi X. yuan, Xu M., Yu X.J. et al. Acetylcholine attenuated TNF-α-induced intracellular Ca2 + overload by inhibiting the formation of the NCX1-TRPC3-IP3R1 complex in human umbilical vein endothelial cells. Journal of Molecular and Cellular Cardiology. 2017; 107: 1–12. DOI:10.1016/j.yjmcc.2017.04.001.; Хоффман Б.Б. Средства, блокирующие адренорецепторы, гл. 10. В кн.: Б.Г. Катцунг. Базисная и клиническая фармакология; т. 1. М.: Бином, 1998.; Daaka Y., Luttrell L.M., Lefkowitz R.J. Switching of the coupling of the β2-adrenergic receptor to different g proteins by protein kinase A. Nature. 1997; 390 (6655): 88–91. DOI:10.1038/36362.; Chesley A., Lundberg M.S., Asai T., Xiao R.P., Ohtani S., Lakatta E.G. et al. The β2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3’-kinase. Circulation Research. 2000; 87 (12): 1172–1179. DOI:10.1161/01.RES.87.12.1172.; Communal C., Singh K., Sawyer D.B., Colucci W.S. Opposing effects of β1- and β2-adrenergic receptors on cardiac myocyte apoptosis: Role of a pertussis toxin-sensitive G protein. Circulation. 1999; 100 (22): 2210–2212. DOI:10.1161/01.CIR.100.22.2210.; https://bulletin.tomsk.ru/jour/article/view/4484

  6. 6
  7. 7
    Academic Journal

    Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 35, № 2 (2020); 163-166 ; Сибирский журнал клинической и экспериментальной медицины; Том 35, № 2 (2020); 163-166 ; 2713-265X ; 2713-2927 ; 10.29001/2073-8552-2020-35-2

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.sibjcem.ru/jour/article/view/991/546; Moritz A.R., Zamcheck N. Sudden and unexpected deaths of young soldiers; diseases responsible for such deaths during World War II. Arch. Pathol. (Chic.). 1946;42(5):459–494.; Cannon W.B. “Voodoo” Death. Am. Anthropol. 1942;44(2):169–181. DOI:10.1525/aa.1942.44.2.02a00010.; Селье Г. Очерки об адаптационном синдроме; пер. с англ. В.И. Кандрора, А.А. Рогова. М.: Медгиз; 1960:254.; Johansson G., Jonsson L., Lannek N., Blomgren L., Lindberg P., Poupa O. Severe stress-cardiopathy in pigs. Am. Heart J. 1974;87(4):451– 457. DOI:10.1016/0002-8703(74)90170-7.; Sato H., Tateishi H., Uchida T. Takotsubo-like left ventricular dysfunction due to multivessel coronary spasm. In: Clinical aspect of myocardial injury: from ischemia to heart failure. Kodama K., Haze K., Hon M., eds. Tokyo: Kagaku Hyoronsha; 1990:56–64 (In Japan.).; Santoro F., Stiermaier T., Tarantino N., Guastafierro F., Graf T., Möller C. et al. Impact of persistent ST elevation on outcome in patients with takotsubo syndrome. Results from the Gеrman Italian Stress Cardiomyopathy (GEIST) registry. Int. J. Cardiol. 2018;255:140–144. DOI:10.1016/j.ijcard.2017.11.068.; Rosu D., Askandar S., Khouzam R.N. Why is reverse takotsubo “Reverse”. South. Med. J. 2017;110(5):381–385. DOI:10.14423/SMJ.0000000000000652.; Takano Y., Ueyama T., Ishikura F. Azelnidipine, unique calcium channel blocker could prevent stress-induced cardiac dysfunction like α β blocker. J. Cardiol. 2012;60(1):18–22. DOI:10.1016/j.jjcc.2012.01.017.; Ishikura F., Takano Y., Ueyama T. Acute effects of beta-blocker with intrinsic sympathomimetic activity on stress-induced cardiac dysfunction in rats. J. Cardiol. 2012;60(6):470–474. DOI:10.1016/j.jjcc.2012.07.004.; Isogai T., Matsui H., Tanaka H., Fushimi K., Yasunaga H. Early β-blocker use and in-hospital mortality in patients with takotsubo cardiomyopathy. Heart. 2016;102(13):1029–1035. DOI:10.1136/heartjnl-2015-308712.; Palla A.R., Dande A.S., Petrini J., Wasserman H.S., Warshofsky M.K. Pretreatment with low-dose β-adrenergic antagonist therapy does not affect severity of takotsubo cardiomyopathy. Clin. Cardiol. 2012;35(8):478– 481. DOI:10.1002/clc.21983.; Miller D.G., Mallov S. Quantitative determination of stress-induced myocardial damage in rats. Pharmacol. Biochem. Behav. 1977;7(2):139–145. DOI:10.1016/0091-3057(77)90198-8.; Mallet R.T., Ryou M.G., Williams A.G., Howard L., Downey H.F. Beta1-adrenergic receptor antagonism abrogates cardioprotective effects of intermittent hypoxia. Basic Res. Cardiol. 2006;101(5):436–446. DOI:10.1007/s00395-006-0599-y.; Loots W., De Clerck F. Diff erential effects of nebivolol on adrenoceptors in the heart and in resistance arterioles in the rat. Quantitative intravital microscopic analysis. Eur. J. Pharmacol. 1990;179(1–2):177–186. DOI:10.1016/0014-2999(90)90416-4.; Maffei A., Di Pardo A., Carangi R., Carullo P., Poulet R., Gentile M.T. et al. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension. 2007;50(4):652–656. DOI:10.1161/HYPERTENSIONAHA.107.094458.; Chesley A., Lundberg M.S., Asai T., Xiao R.P., Ohtani S., Lakatta E. et al. The β2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3’-kinase. Circ. Res. 2000;87(12):1172–1179. DOI:10.1161/01.RES.87.12.1172.; Communal C., Singh K., Sawyer D.B., Colucci W.S. Opposing effects of β1- and β2-adrenergic receptors on cardiac myocyte apoptosis: Role of a pertussis toxin-sensitive G protein. Circulation. 1999;100(22):2210–2212. DOI:10.1161/01.CIR.100.22.2210.; Germack R., Dickenson J.M. Induction of β3-adrenergic receptor functional expression following chronic stimulation with noradrenaline in neonatal rat cardiomyocytes. J. Pharmacol. Exp. Ther. 2006;316(1):392–402. DOI:10.1124/jpet.105.090597.; Laukova M., Tillinger A., Novakova M., Krizanova O., Kvetnansky R., Myslivecek J. Repeated immobilization stress increases expression of β3 -adrenoceptor in the left ventricle and atrium of the rat heart. Stress Health. 2014;30(4):301–309. DOI:10.1002/smi.2515.; https://www.sibjcem.ru/jour/article/view/991

  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
    Academic Journal

    Πηγή: Vavilov Journal of Genetics and Breeding; Том 21, № 7 (2017); 798-803 ; Вавиловский журнал генетики и селекции; Том 21, № 7 (2017); 798-803 ; 2500-3259

    Περιγραφή αρχείου: application/pdf

    Relation: https://vavilov.elpub.ru/jour/article/view/1228/994; Alekhina T.A., Gilinsky M.A., Kolpakov V.G. Catecholamines level in the brain of rats with a genetic predisposition to catatonia. Biogenic Amines. 1994;10(5):443-449.; Alsene K.M., Carasso B.S., Connors E.E., Bakshi V.P. Disruption of prepulse inhibition after stimulation of central but not peripheral a-1 adrenergic receptors. Neuropsychopharmacology. 2006;31(10):2150-2161. DOI 10.1038/sj.npp.1300989.; Barykina N.N., Alekhina T.A., Chuguy V.F., Petrenko O.I., Popova N.K., Kolpakov V.G. Negative correlation between cataleptic freezing and prepulse inhibition of the startle reflex in rats. Rossiy-skiy fiziologicheskiy zhurnal im. I.M. Sechenova = I.M. Sechenov Physiological Journal. 2002;88(11):1388-1393. (in Russian); Barykina N.N., Chepkasov I.L., Alekhina T.A., Kolpakov V.G. Breeding of Wistar rats for predesposition to catalepsy. Genetika = Genetics (Moscow). 1983;19(12):2014-2021. (in Russian); Carasso B.S., Bakshi V.P., Geyer M.A. Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats. Neuropharmacology. 1998;37(3):401-404. https://doi.org/10.1016/S0028-3908(98) 00051-3.; Doze V.A., Handel E.M., Jensen K.A., Darsie B., Luger E.J., Hasel-ton J.R., Talbot J.N., Rorabaugh B.R. Alpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse. Brain Res. 2009;1285:148-157. DOI 10.1016/j.brainres.2009.06.035.; Ellenbroek B.A., Geyer M.A., Cools A.R. The behavior of APO-SUS rats in animal models with construct validity for schizophrenia. J. Neurosci. 1995;15(11):7604-7611. DOI 0270-6474/95/157604-08$05.00/O.; Hoffman H.S., Wible B.L. Role of weak signals in acoustic startle. J. Acoust. Soc. Am. 1970;47:489-497. DOI 10.1121/1.1911919.; Hohnadel E., Bouchard K., Terry A.V. Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology. 2007;52(2):542-551. DOI 10.1016/j.neu-ropharm.2006.08.025.; Joober R., Boksa P., Benkelfat C., Rouleau G. Genetics of schizophrenia: from animal models to clinical studies. J. Psychiatry Neurosci. 2002;27(5):336-347.; Kolpakov V.G., Kulikov A.V., Alekhina T.A., Chuguy V.F., Petrenko O.I., Barykina N.N. Catatonia or depression: The GC rat strain as an animal model of psychopathology. Genetika = Genetics (Moscow). 2004;40(6):827-834. DOI 10.1023/B:RUGE.0000033315.79449.d4. (in Russian); Kvetnansky R., Sabban E.L., Palkovits M. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol. Rev. 2009;89(2):535-606. DOI 10.1152/physrev.00042.2006.; Le Pen G., Moreau J.L. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology. 2002;27(1):1-11. DOI 10.1016/S0893-133X(01)00383-9.; Lehmann J., Pryce C.R., Feldon J. Sex differences in the acoustic startle response and prepulse inhibition in Wistar rats. Behav. Brain Res. 1999;104(1-2):113-117. DOI 10.1016/S0166-4328(99)00058-3.; Li L., Du Y., Li N., Wu X., Wu Y. Top-down modulation of prepulse inhibition of the startle reflex in humans and rats. Neurosci. Biobehav. Rev. 2009;33(8):1157-1167. DOI 10.1016/j.neubiorev.2009.02.001.; Li L., Korngut L.M., Frost B.J., Beninger R.J. Prepulse inhibition following lesions of the inferior colliculus: prepulse intensity functions. Physiol. Behav. 1998;65(1):133-139. DOI 10.1016/S0031-9384(98)00143-7.; Martinez-Gras I., Rubio G., del Manzano B.A., Rodriguez-Jimenez R., Garcia-Sanchez F., Bagney A., Leza J.C., Borrell J. The relationship between prepulse inhibition and general psychopathology in patients with schizophrenia treated with long-acting risperidone. Schizophr. Res. 2009;115(2-3):215-221. DOI 10.1016/j.schres.2009.09.035.; Perry W., Minassian A., Lopez B., Maron L., Lincoln A. Sensorimotor gating deficits in adults with autism. Biol. Psychiatry. 2007;61(4): 482-486. DOI 10.1016/j.biopsych.2005.09.025.; Popova N.K., Barykina N.N., Alekhina T.A., Naumenko K.S., Kulikov A.V. Effects of 5-HT2-receptor blockade on the startle reflex and its prespulse inhibition in different mouse and rats strains. Ros-siyskiy fiziologicheskiy zhurnal im. I.M. Sechenova = I.M. Seche-nov Physiological Journal. 1999;85(6):857-864. (in Russian); Powell S.B., Zhou X., Geyer M.A. Prepulse inhibition and genetic mouse models of schizophrenia. Behav. Brain Res. 2009;204(2):282-294. DOI 10.1016/j.bbr.2009.04.021.; Rohleder C., Jung F., Mertgens H., Wiedermann D., Sue M., Neumaier B., Graf R., Leweke F.M., Endepols H. Neural correlates of sensorimotor gating: a metabolic positron emission tomography study in awake rats. Front. Behav. Neurosci. 2014;8:178. DOI 10.3389/fnbeh.2014.00178.; Ryazanova M.A., Fedoseeva L.A., Ershov N.I., Efimov V.M., Mar-kel A.L., Redina O.E. The gene-expression profile of renal medulla in ISIAH rats with inherited stress-induced arterial hypertension. BMC Genet. 2016;17(3):166-173. DOI 10.1186/s12863-016-0462-6.; Ryazanova M.A., Igonina T.N., Alekhina T.A., Prokudina O.I. The increase in the proportion of nervous animals among those bred for catatonia: The participation of central adrenergic receptors in catatonic reactions. Genetika = Genetics (Moscow). 2012;48(11):1-8. DOI 10.1134/S1022795412100092. (in Russian); Shishkina G.T., Kalinina T.S., Popova N.K., Dygalo N.N. Influence of neonatal short-term reduction in brainstem alpha2A-adrenergic receptors on receptor ontogenesis, acoustic startle reflex, and prepulse inhibition in rats. Behav. Neurosci. 2004;118(6):1285-1292. DOI 10.1037/0735-7044.118.6.1285.; Stone E.A., Grunewald G.L., Lin Y., Ahsan R., Rosengarten H., Kramer H.K., Quartermain D. Role of epinephrine stimulation of CNS al-adrenoceptors in motor activity in mice. Synapse. 2003a;49:67-76. DOI 10.1002/syn.10212.; Stone E.A., Lin Y., Quartermain D. Immobility from administration of the al-adrenergic antagonist, terazosin, in the IVth ventricle in rats. Neurosci. Lett. 2003b;353:231-233. DOI 10.1016/j.neulet. 2003.09.033.; Stone E.A., Quartermain D. Alpha-1-noradrenergic neurotransmission, corticosterone, and behavioral depression. Biol. Psychiatry. 1999; 46:1287-1300. DOI 10.1016/S0006-3223(99)00234-6.; Stone E.A., Zhang Y., Rosengarten H., Yeretsian J., Quartermain D. Brain alpha 1-adrenergic neurotransmission is necessary for behavioral activation to environmental change in mice. Neuroscince. 1999;94:1245-1252. DOI 10.1016/S0306-4522(99)00394-2.; Swerdlow N.R., Light G.A., Trim R.S., Breier M.R., Hines S.R., Powell S.B. Forebrain gene expression predicts deficits in sensorimotor gating after isolation rearing in male rats. Behav. Brain Res. 2013; 257:118-128. DOI 10.1016/j.bbr.2013.09.005.; Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. ArchGen Psychiatry. 1994;51(2):139-154. DOI 10.1001/archpsyc.1994.03950020063007.; Swerdlow N.R., Shilling P.D., Breier M. Trim R.S., Light G.A., Marie R.S. Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats. Psychopharmacology. 2012;224(3):349-362. DOI 10.1007/s00213-012-2758-1.; Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology. 2008;199(3):331-388. DOI 10.1007/s00213-008-1072-4.; Weber M., Chang W.L., Breier M.R., Yang A., Millan M.J., Swerd-low N.R. The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats. Eur. Neuropsychopharmacol. 2010;20(6): 421-425. DOI 10.1016/j.euroneuro.2010.02.011.; Yeomans J.S., Lee J., Yeomans M.H., Steidl S., Li L. Midbrain pathways for prepulse inhibition and startle activation in rat. Neuroscience. 2006;142(4):921-929. DOI 10.1016/j.neuroscience.2006.06.025.; https://vavilov.elpub.ru/jour/article/view/1228

  14. 14
    Academic Journal

    Πηγή: Meditsinskiy sovet = Medical Council; № 2 (2017); 122-127 ; Медицинский Совет; № 2 (2017); 122-127 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-2

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/1735/1681; Abrams P. The standartisation of terminology of lower urinary tract function. Neurourol. and Urodyn, 2002, 21: 167-178.; Гаджиева Ж.К. Нарушения мочеиспускания: руководство. Под ред. Ю.Г. Аляева. М.: ГЭОТАР-Медиа, 2010. 176 с.; Пушкарь Д.Ю. Гиперактивный мочевой пузырь у женщин. М.: МЕД пресс-информ, 2003. 160 с.; Джавад-Заде М.Д., Державин В.М., Вишневский Е.Л. Нейрогенные дисфункции мочевого пузыря. М.: Медицина, 1989.; Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A populationbased prevalence study. BJU Int, 2001, 87: 760–6.; Вишневский Е.Л., Пушкарь Д.Ю., Лоран О.Б., Данилов В.В., Вишневский А.Е. Урофлоуметрия. М., 2004: 263, 176–183, 183–208.; Moller LA, Lose G, Jorgensen T. Risk factors lower urinary tract symptoms in women 40 to 60 years of age. Obstet. Gynecol., 2000, 96: 446–51.; Cruz F. Vanilloid receptor and detrusor instability. Neurology and Urodynamics, 2009: 29–34.; Takeda M, Obara K, Mizusawa T et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther., 1999, 288, 3: 1367–1373.; Takeda H, Yamazaki Y, Akahane M et al. Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J. Pharmacol. Exp. Ther., 2000, 293(3): 939–945.; Otsuka A, Shinbo H, Matsumoto R et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 377(4–6): 473–481.; Liu Hsin-Tzu, Chancellor MB, Kuo H-Ch. Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection. European urology, 2009, 56: 700-707.; Liu Hsin-Tzu, Chancellor MB, Kuo H-Ch. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU international, 2009, 103(12): 1668-72.; Lesch KP, Merschdorf U. Impulsivity, aggression, and serotonin: a molecular psychobiological perspective. Behav Sci Law, 2000, 18: 581-604.; Zifa E, Fillion G. 5-Hydroxytryptamine receptors. Pharmacol. Rev., 1992, 44: 401-458.; Michel M, Ochodnicky P, Homma Y and Igawa Y. β-adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther, 2011, 131: 40–49.; Stenberg F, Heimer G, Ulmsten U. The prevalence of urogenital symptoms in postmenopausal women. Maturitas, 1995, 22(Suppl): 17–20.; Кулаков В.И., Аполихина И.А. Недержание мочи у женщин: новые возможности в диагностике и лечении. Гинекология, 2004, 4(3): 103–5.; Groat WC. Afferent nerve regulation of bladder function in health and disease. Handb. Exp. Pharmacol., 2009, 194: 91-138.; Abrams P and Wein. Overactive bladder and its treatments. Urology, 2000, 55(sup.).; Mukerji G et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. I. Urol., 2006, 176(1): 367-373.; Mulsant B, Pollock B, Kirshner M, Shen C, Dodge H and Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry, 2003, 60: 198–203.; Milsom I, Abrams P, Cardozo L, Roberts R, Thuroff J, Wein A. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int., 2001, 87: 760–766.; Wein AJ Rackley R.R. Overactive bladder: a better understanding of pathophysiology, diagnosis and management J Urol, 2006, 175(3 Pt 2): S5–10; Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther., 1999, 288: 1367–1373.; Sacco E, Tienforti D, D’Addessi A, Pinto F, Racioppi M, Totaro A, D’Agostino D, Marangi F, Bassi P. Social, economic, and health utility considerations in the treatment of overactive bladder. J. Urol., 2010, 2: 11–24.; Gruneberger A. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. Br. J. Obstetr. Gynaecol., 1984, 91: 275–278.; FDA Summary of safety and efficacy as basis for Advisory Committee briefing document for mirabegron, 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Reproductive HealthDrugsAdvisoryCommittee/UCM298284.pdf; Chapple C, Amarenco G, Lopez Aramburu M, Everaert K, Liehne J, Lucas M et al. A proof-ofconcept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn, 2013a, 32: 1116–1122.; Chapple C, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele J, Bosman B et al. (2013b) A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J, 24: 1447–1458.; Nitti V, Herschorn S, Auerbach S et al. The selective [beta] 3-adrenoreceptor agonist mirabegron is effective and well tolerated in patients with overactive bladder syndrome. J. Urol., 2011, 185(4): e783–e784.; Khullar V, Amarenco G, Angulo JC et al. Efficacy and tolerability of mirabegron, a β(3)- adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur. Urol., 2013, 63(2): 283–295.; Chapple C, Kaplan S, Mitcheson H et al. Randomised, double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)adrenoceptor agonist, in overactive bladder (OAB). Eur. Urol., 2013, 62(2): 296–305.; Rossanese M, Novara G, Challacombe B, Iannetti A, Dasgupta P and Ficarra V. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a beta(3)-adrenoceptor agonist (mirabegron) for overactive bladder (OAB). BJU Int, 2015, 115: 32–40.; Rosa G, Ferrero S, Nitti V, Wagg A, Saleem T and Chapple C. Cardiovascular safety of beta3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol, 2016, 69: 311–323.; Baber RJ, Panay N, Fenton A и рабочая группа IMS, 2016.

  15. 15
    Academic Journal

    Πηγή: Scientific studies: from theory to practice; № 1(11); 27-30 ; Научные исследования: от теории к практике; № 1(11); 27-30 ; ISSN: 2413-3957 ; 2413-3957

    Περιγραφή αρχείου: text/html

    Relation: info:eu-repo/semantics/altIdentifier/pissn/2413-3957; https://interactive-plus.ru/e-articles/339/Action339-118128.pdf; 1. Гусева Е.П. Влияние катехоламинов на степень агрегации и сорбционную способность эритроцитов при сердечной патологии / Е.П. Гусева, И.А. Тихомирова, А.В. Муравьев, Ю.Н. Волков // Гемореалогия в микро- и макроциркуляции: Материалы международной конференции. – Ярославль, 2005. – С. 204.; 2. Кленова Н.А. Строение, метаболизм и функциональная активность эритроцитов человека в норме и патологии / Н.А. Кленова, Р.О. Кленов. – Самара, 2009.; 3. Тихомирова И.А. Роль экстрацеллюлярных, мембранных и внутриклеточных факторов в процессе агрегации эритроцитов: Автореф. дис. … д-ра биол. наук / И.А. Тихомирова. – Ярославль, 2006. – 48 с.; 4. Bree F. Beta adrenoceptors of human red blood cells, determination of their subtypes / F. Bree, I. Gault, P. d’Athis, J.P. Tillement // Biochem. Pharmacol. – 1984. – Vol. 33. – №24. – P. 4045–4050.; 5. Devanathan S. Plasmon-Waveguide Resonance Studies of Ligand Binding to the Human β-Adrenergic Receptor / S. Devanathan, Z. Yao, Z. Salamon [et al.] // Biochemistry. – 2004. – Vol. 43. – №11. – P. 3280–3288.; 6. Hines P.S. Novel epinephrine and cyclic cAMP -mediated action on BCAM/Lu dependent sickle (SS) RBC adhesion / P.S. Hines, Q. Zen, S.N. Burney [et al.] // Blood. – 2003. – Vol. 101. – №8. – P. 3281–3287. – 114 с.; 7. Horga J.F. A beta-2-adrenergic receptor activates adenilate-cyclase in human erythrocyte membranes at physiological calcium plasma concentration / J.F. Horga, J. Gisbert, J.C. De Agustin [et al.] // Blood. Сell. Мol. Dis. – 2000. – Vol. 3. – P. 223–228.

  16. 16
  17. 17
  18. 18
  19. 19
  20. 20